Literature DB >> 11919418

Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts.

Frédéric Féger1, Antoine Ribadeau Dumas, Laurence Leriche, Peter Valent, Michel Arock.   

Abstract

Mastocytosis is a heterogeneous group of hematopoietic disorders characterized by abnormal growth and accumulation of mast cells (MC) in one or more organs. Clinical symptoms occur as a result of the release of chemical mediators and/or of pathologic infiltration of MC in various tissues. Although the initial events leading to mastocytosis have not yet been unraveled, acquired alterations in the c-kit gene coding for the receptor of stem cell factor (SCF), a major cytokine involved in MC growth, have been described in a significant number of patients. Of particular interest are point mutations resulting in a constitutively activated SCF receptor. Such mutations are probably involved in the abnormal (SCF-independent) proliferation of MC in these patients. New therapeutic strategies may be envisaged to inhibit the deregulated kinase activity of these mutant forms of c-kit. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11919418     DOI: 10.1159/000048179

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  28 in total

1.  Systemic mastocytosis: progressive evolution of an occult disease into fatal mast cell leukemia: unique findings on an unusual hematological neoplasm.

Authors:  T Gülen; B Sander; G Nilsson; J Palmblad; K Sotlar; H-P Horny; H Hägglund
Journal:  Med Oncol       Date:  2012-06-03       Impact factor: 3.064

2.  High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V.

Authors:  Robert Fritsche-Polanz; Marika Fritz; Andrea Huber; Karl Sotlar; Wolfgang R Sperr; Christine Mannhalter; Manuela Födinger; Peter Valent
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

3.  Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536.

Authors:  Barbara Peter; Karoline V Gleixner; Sabine Cerny-Reiterer; Harald Herrmann; Viviane Winter; Emir Hadzijusufovic; Veronika Ferenc; Karina Schuch; Irina Mirkina; Hans-Peter Horny; Winfried F Pickl; Leonhard Müllauer; Michael Willmann; Peter Valent
Journal:  Haematologica       Date:  2011-01-17       Impact factor: 9.941

4.  Identification of oncostatin M as a STAT5-dependent mediator of bone marrow remodeling in KIT D816V-positive systemic mastocytosis.

Authors:  Gregor Hoermann; Sabine Cerny-Reiterer; Andrea Perné; Miriam Klauser; Konrad Hoetzenecker; Katharina Klein; Leonhard Müllauer; Marion Gröger; Sebastian M B Nijman; Walter Klepetko; Peter Valent; Matthias Mayerhofer
Journal:  Am J Pathol       Date:  2011-03-31       Impact factor: 4.307

Review 5.  Midostaurin: a magic bullet that blocks mast cell expansion and activation.

Authors:  P Valent; C Akin; K Hartmann; T I George; K Sotlar; B Peter; K V Gleixner; K Blatt; W R Sperr; P W Manley; O Hermine; H C Kluin-Nelemans; M Arock; H-P Horny; A Reiter; J Gotlib
Journal:  Ann Oncol       Date:  2017-10-01       Impact factor: 32.976

6.  H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells.

Authors:  Emir Hadzijusufovic; Barbara Peter; Karoline V Gleixner; Karina Schuch; Winfried F Pickl; Tuddow Thaiwong; Vilma Yuzbasiyan-Gurkan; Irina Mirkina; Michael Willmann; Peter Valent
Journal:  Exp Hematol       Date:  2010-06-01       Impact factor: 3.084

7.  Systemic mastocytosis with associated acute myelogenous leukemia.

Authors:  Leah Zhrebker; Barry Cooper; John R Krause
Journal:  Proc (Bayl Univ Med Cent)       Date:  2014-01

8.  Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.

Authors:  Karl Sotlar; Anja Bache; Florian Stellmacher; Burkhard Bültmann; Peter Valent; Hans-Peter Horny
Journal:  J Mol Diagn       Date:  2007-12-28       Impact factor: 5.568

9.  Genetic and pharmacologic evidence implicating the p85 alpha, but not p85 beta, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis.

Authors:  Veerendra Munugalavadla; Emily C Sims; Jovencio Borneo; Rebecca J Chan; Reuben Kapur
Journal:  Blood       Date:  2007-05-04       Impact factor: 22.113

10.  Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology.

Authors:  Peter Valent
Journal:  Am J Cancer Res       Date:  2013-04-03       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.